Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 10/20 | 0.82 |
| ▸ | AVPR1A | P37288 | 8/20 | 0.82 |
| ▸ | AVPR2 | P30518 | 6/20 | 0.82 |
| ▸ | AVPR1B | P47901 | 6/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.78 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.78 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lypressin SCHEMBL1650587 | 0.97 | OXTR (0.87) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Lypressin SCHEMBL33287 | 0.97 | OXTR (0.87) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Lypressin SCHEMBL29471105 | 0.96 | OXTR (0.84) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Ornipressin SCHEMBL1650220 | 0.96 | AVPR1A (0.88) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Ornipressin SCHEMBL296322 | 0.96 | AVPR1A (0.88) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Felypressin SCHEMBL361197 | 0.94 | AVPR1A (0.82) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Felypressin SCHEMBL31138866 | 0.94 | AVPR1A (0.82) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Felypressin SCHEMBL33291 | 0.94 | AVPR1A (0.82) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Felypressin SCHEMBL1650172 | 0.94 | AVPR1A (0.82) | OXTRAVPR1AAVPR2AVPR1BTBXA2R | |
| Ornipressin SCHEMBL4410141 | 0.94 | AVPR1A (0.85) | OXTRAVPR1AAVPR2AVPR1BTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220031668-A1 | METHODS OF INHIBITING PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 2 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220031668-A1 | METHODS OF INHIBITING PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 2 | PLOD2, TPSB2, PLOD1 | OXTR 3279/4885AVPR1A 2821/4885AVPR2 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.